A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis

Ticagrelor With or Without Aspirin After Complex PCI

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy

Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study

Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)